Botulinum toxin A injectable - Allergan

Drug Profile

Botulinum toxin A injectable - Allergan

Alternative Names: Botox; GSK 1358820; Onabotulinum toxin A; Vistabel; Vistabex

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan
  • Developer Allergan; GlaxoSmithKline; Johns Hopkins University; Temple University; Wake Forest University School of Medicine
  • Class Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscle spasticity; Torticollis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Facial-wrinkles; Glabellar lines; Hyperhidrosis; Migraine; Muscle spasticity; Neurogenic bladder; Overactive bladder; Strabismus; Torticollis
  • Registered Equinus foot deformity
  • Phase III Raynaud's disease
  • Phase II Carpal tunnel syndrome; Gastrointestinal disorders; Herpes labialis; Hypertrophy; Major depressive disorder; Musculoskeletal pain; Pain; Premature ejaculation
  • Phase I/II Pruritus
  • No development reported Benign prostatic hyperplasia
  • Discontinued Diabetic gastroparesis; Gilles de la Tourette's syndrome

Most Recent Events

  • 18 Dec 2017 Preregistration for Facial wrinkles in France (Intradermal) before December 2017
  • 18 Dec 2017 Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) recommends approval of botulinum toxin A for Facial wrinkles (moderate to severe forehead lines)
  • 03 Oct 2017 Registered for Facial wrinkles (Forehead Lines Associated with Frontalis Muscle Activity) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top